Thursday, November 21, 2024
11/21/2024
ABSTRACT Heparin-induced thrombocytopenia (HIT) is the most common drug-induced immune thrombocytopenia and can lead to catastrophic thrombosis in an affected patient. Antibodies that recognize the platelet alpha-granule protein, platelet factor 4 (PF4), in a complex with heparin are central to HIT pathogenesis. Human B cells have extensive heterogeneity. Innate-like B cells, such as B1 and marginal zone (MZ) B cells, later germinal center (GC) B cells, different types of memory B cells, and extrafollicular plasmablasts all play an importance and unique role in the development of humoral immunity. Rapid onset of HIT antibody production and apparent lack of immunologic memory suggest T-cell independence whereas IgG antibodies typical of HIT argue for T cell involvement. The profound heterogeneity of human B cells and the ambiguous features of the HIT antibody response have confounded efforts to identify the pathogenic B cells and characterize the atypical immune response in HIT patients. In a mouse model, we have demonstrated that MZ B cells play a critical role in HIT antibody production. In the immediate past grant period, we discovered that in mice, breakdown of immunologic tolerance was involved in HIT antibody production and T helper cells and regulatory T cells could mediate the production of PF4/heparin-specific HIT antibodies. We also identified several novel pathways controlling B cell tolerance that was critical for controlling production of autoantibodies. Importantly, from HIT human patients, we cloned PF4/heparin-specific and platelet-activating antibodies possessing a unique RKH- or Y5-motif in the heavy chain complementarity determining region 3 (HCDR3) region that contributes the most to affinity and specificity of antigen binding. We found that a higher percentage of PF4/heparin-specific B cells, compared to the control B cells, exhibited extrafollicular B-cell features and an atypical memory B cell (atyMB) phenotype. Based on these findings, we hypothesize that PF4/heparin-specific B cells undergo extrafollicular response to follow a distinct differentiation path from activated naïve B cells first into atyMBs and then into plasmablasts in HIT patients. To test this hypothesis, we will (1) study the characteristics of PF4/heparin-specific B cells in HIT patients through integrative analysis of phenotypical, transcriptional and epigenetic responses of these B cells and (2) investigate the origin and developmental trajectory of PF4/heparin-specific B cells that produce platelet- activating antibodies in HIT patients. The proposed studies will identify the key features of PF4/heparin-specific B cells and their correlation with disease progression and severity and will discover the evolution of PF4/heparin- specific B-cell response. Completion of the proposed studies will provide novel insights into the molecular pathogenesis of HIT and guide future diagnosis, prevention and treatment of this potentially devastating disease.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
